Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal OX40-specific antibody. Vonlerolizumab can be used for the research of cancer[1].
References
[1] Marin-Acevedo JA, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar 15;11(1):39. DOI:10.1186/s13045-018-0582-8
